Peri-operative SLOG for Localized Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

August 24, 2024

Study Completion Date

August 24, 2025

Conditions
Pancreatic Ductal AdenocarcinomaPancreas Cancer
Interventions
DRUG

S-1, leucovorin, oxaliplatin and gemcitabine

"Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day"

Trial Locations (3)

Unknown

RECRUITING

Kaohsiung Medical University Hospital, Kaohsiung City

RECRUITING

National Cheng-Kung University Hospital, Tainan City

RECRUITING

National Institute of Cancer Research, Tainan City

All Listed Sponsors
lead

National Health Research Institutes, Taiwan

OTHER